Winship Cancer Institute of Emory University | Strategic Alliance Partners

March 31, 2020

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

March 28, 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

March 24, 2020

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

February 26, 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

January 17, 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

January 13, 2020

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

January 11, 2020

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

January 10, 2020

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

December 27, 2019

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

December 24, 2019

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

December 23, 2019

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

December 23, 2019

Ajay K. Nooka, MD, MPH, FACP, discusses the shift in induction regimens in multiple myeloma and the impact of daratumumab (Darzalex) on the space.

December 05, 2019

Sagar Lonial, MD, FACP, discusses important additions to the treatment arsenal in relapsed/refractory multiple myeloma.

December 04, 2019

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

December 03, 2019

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

November 21, 2019

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

November 16, 2019

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

November 16, 2019

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

November 14, 2019

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

November 12, 2019

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.